QuidelOrtho Reagents
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Centers for Disease Control and Prevention (CDC), Office of Acquisition Services, intends to award a sole source, firm-fixed-price purchase order to QuidelOrtho Corporation for reagents required for their VITROS 3600 systems. This is a combined synopsis/solicitation, and while the CDC intends a sole source award, other responsible sources may submit capability statements. Responses are due by February 19, 2026.
Scope of Work
This procurement is for OEM support reagents specifically for the VITROS 3600 systems utilized by the Division of Viral Hepatitis Laboratory Branch at CDC. QuidelOrtho Corporation is identified as the original equipment manufacturer (OEM) and the only known source with access to the proprietary reagents and diagnostic support necessary for these systems, ensuring compliance with manufacturer specifications.
Contract & Timeline
- Type: Sole Source, Firm-Fixed-Price Purchase Order (Combined Synopsis/Solicitation)
- Authority: FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c)(1)
- Set-Aside: None (Open Market, Sole Source Intent)
- NAICS: 325413 (Optical Instruments, Test Equipment, Components And Accessories) with a small business size standard of 1,250 employees
- Response Due: Thursday, February 19, 2026, by 5:00 PM EST
- Published: February 13, 2026
Evaluation
The CDC intends to award a sole source contract to QuidelOrtho Corporation. This notice is not a request for competitive quotations. However, responsible sources who believe they can meet the government's requirement may submit a capability statement demonstrating their ability to provide the required OEM reagents. The government will consider responses to determine if a competitive procurement is feasible, but this decision is solely at the government's discretion.
Additional Notes
Responses must reference RFQ notice 75D30126Q78789 and be emailed to Gary Morgan, Contract Specialist, at gmorgan1@cdc.gov. No further notice will be posted.